Consider This Before Taking a Position in GMED

Shares of Health Care sector company Globus Medical moved 0.6% today, and are now trading at a price of $54.92. The mid-cap stock's daily volume was 89,872 compared to its average volume of 1,309,139. The S&P 500 index returned a 0.0% performance.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company is based in Audubon and has 2,600 full time employees. Its market capitalization is $7,567,590,912.

12 analysts are following Globus Medical and have set target prices ranging from $53.0 to $83.0 per share. On average, they have given the company a rating of hold. At today's prices, GMED is trading -15.18% away from its average analyst target price of $64.75 per share.

Over the last year, GMED shares have gone down by -26.3%, which represents a difference of -47.4% when compared to the S&P 500. The stock's 52 week high is $80.04 per share and its 52 week low is $43.39. With average free cash flows of $135.2 Million that have been growing at an average rate of 3.0% over the last 6 years, Globus Medical declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 202,800 73,733 129,067 23.6
2022 178,468 74,047 104,421 -52.4
2021 276,274 56,898 219,376 62.34
2020 198,793 63,658 135,135 33.5
2019 171,975 70,750 101,225 -16.99
2018 181,643 59,697 121,946
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.